Browse the corpus

REFERENCES Iversen, P, Johansson JE, Lodding P, et al, “Bicalutamide (150 mg) Versus Placebo as Immediate Therapy Alone or as Adjuvant to Therapy With Curative Intent for Early Nonmetastatic Prostate Cancer: 5.3 Year Median Followup from the Scandinavian Prostate Cancer Group Study Number 6,” J Urol , 2004, 172(5 Pt 1):1871-6. Levine GN, D’Amico AV, Berger P, et al, “Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association,” Circulation , 2010, 121:831-38. [PubMed 20124128 ] Loblaw DA, Virgo KS, Nam R, et al, “Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline,” J Clin Oncol , 2007, 25(12):1596-605. [PubMed 17404365 ] McLeod DG, Iversen P, See WA, et al, “Bicalutamide 150 mg Plus Standard Care vs Standard Care Alone for Early Prostate Cancer,” BJU Int , 2005, 97(2):247-54. [PubMed 16430622 ] McLeod DG, See WA, Klimberg I, et al, “The Bicalutamide 150 mg Early Prostate Cancer Program: Findings of the North American Trial at 7.7-Year Median Followup,” J Urol , 2006, 176(1):75-80. [PubMed 16753373 ] National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Prostate Cancer,” Version 3.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Schellhammer P, Sharifi R, Block N, et al, “A Controlled Trial of Bicalutamide Versus Flutamide, Each in Combination With Luteinizing Hormone-Releasing Hormone Analogue Therapy, in Patients With Advanced Prostate Cancer. Casodex Combination Study Group.” Urology , 1995, 45(5):745-52. [PubMed 7538237 ] Schellhammer PF, Sharifi R, Block NL, et al, “Clinical Benefits of Bicalutamide Compared With Flutamide in Combined Androgen Blockade for Patients With Advanced Prostatic Carcinoma: Final Report of a Double-Blind, Randomized, Multicenter Trial. Casodex Combination Study Group,” Urology , 1997, 50(3):330-6. [PubMed 9301693 ] Topic 9154 Version 43.0

Schellhammer PF, Sharifi R, Block NL, et al, “Clinical Benefits of Bicalutamide Compared With Flutamide in Combined Androgen Blockade for Patients With Advanced Prostatic Carcinoma: Final Report of a Double-Blind, Randomized, Multicenter Trial. Casodex Combination Study Group,” Urology , 1997, 50(3):330-6. [PubMed 9301693 ] Topic 9154 Version 43.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [0603-122.72.76.133-81EFD22CC2-S244013.14]